GlassScriptPhysician profile
Giovanni Geslani
NPI 1962638858
$414,524.37
in general payments reported to CMS, 2019-2025
43 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $11K · 2021: $35K · 2022: $69K · 2023: $49K · 2024: $104K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $164K · Consulting Fee: $27K · Travel and Lodging: $21K · Food and Beverage: $20K · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $163,748.00 |
| Consulting Fee | $26,935.00 |
| Travel and Lodging | $20,924.31 |
| Food and Beverage | $20,430.71 |
| Education | $206.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154,518.46 | 2019-2025 | |
| Janssen Biotech, INC. | $137,041.79 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $40,365.82 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $32,780.11 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $27,396.12 | 2019-2025 | |
| Amgen INC. | $4,843.85 | 2019-2025 | Enbrel, Krystexxa, Evenity |
| Glaxosmithkline, LLC. | $2,585.20 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $1,873.48 | 2019-2025 | Taltz, Zepbound |
| Pfizer INC. | $1,660.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,598.91 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $1,505.31 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $1,357.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,235.79 | 2019-2025 | Orencia |
| Merck Sharp & Dohme LLC | $1,162.89 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $707.47 | 2021-2025 | Lupkynis |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $561.47 | 2021-2025 | Acthar |
| Genentech USA, INC. | $470.29 | 2019-2025 | Actemra, Rituxan |
| Organon LLC | $384.94 | 2023-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.19 | 2022-2025 | Cyltezo, Ofev |
| Radius Health, INC. | $291.12 | 2019-2025 | Tymlos |
| Hikma Pharmaceuticals USA | $257.34 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $217.65 | 2023-2025 | Idacio, Tyenne |
| Celgene Corporation | $211.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $132.29 | 2019-2025 | Strensiq |
| Sobi, INC | $125.34 | 2019-2025 | |
| Novo Nordisk INC | $124.79 | 2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $107.99 | 2019-2021 | |
| Pacira Therapeutics, INC. | $96.39 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $78.94 | 2022-2023 | Reditrex |
| Medexus Pharma, INC. | $63.51 | 2019-2020 | |
| Zyla Life Sciences, INC. | $57.05 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $56.38 | 2024 | Arcalyst |
| Antares Pharma, INC. | $55.55 | 2019-2020 | |
| Kyowa Kirin, INC. | $49.40 | 2024-2025 | Crysvita |
| Ani Pharmaceuticals, INC. | $45.02 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Scilex Pharmaceuticals INC. | $34.18 | 2024 | |
| Progentec Diagnostics, INC. | $33.00 | 2020 | |
| Invivyd INC | $30.46 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals, LTD. | $29.22 | 2023 | Arcalyst |
| Shield Therapeutics INC | $27.97 | 2025 | |
| Mylan Institutional INC. | $23.25 | 2023 | |
| Celltrion USA INC. | $14.34 | 2023 | Yuflyma |
| Zimmer Biomet Holdings, INC. | $13.93 | 2024 | Gps III Platelet Concentration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giovanni Geslani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.